TY - JOUR
T1 - Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a)
AU - Yamauchi, Kazunobu
AU - Tanahashi, Yoshifumi
AU - Okada, Mitsuhiro
AU - Tsuzuki, Jitsuki
AU - Sato, Akihiko
AU - Abe, Kazunari
AU - Inagaki, Haruo
AU - Agetsuma, Hirotaka
AU - Hattori, Ritsuo
AU - Izawa, Hideo
N1 - Funding Information:
We gratefully thank Professor Hidehiko Saito for his helpful suggestions and acknowledge the secretarial assistance of Aki Ohtake. This study was supported in part by Sanwa Kagaku Kenkyujo Co. Ltd., Nagoya, Japan.
PY - 1995
Y1 - 1995
N2 - The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 out-patients who had serum Lp(a) levels higher than 20 mg/dL. The mean (±SE) levels of Lp(a) decreased from 33.6 ± 2.3 mg/dL to 23.5 ± 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apoliprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).
AB - The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 out-patients who had serum Lp(a) levels higher than 20 mg/dL. The mean (±SE) levels of Lp(a) decreased from 33.6 ± 2.3 mg/dL to 23.5 ± 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apoliprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).
UR - http://www.scopus.com/inward/record.url?scp=0028940024&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028940024&partnerID=8YFLogxK
U2 - 10.1016/0149-2918(95)80006-9
DO - 10.1016/0149-2918(95)80006-9
M3 - Article
C2 - 7758061
AN - SCOPUS:0028940024
VL - 17
SP - 52
EP - 59
JO - Clinical Therapeutics
JF - Clinical Therapeutics
SN - 0149-2918
IS - 1
ER -